Trial Now Recruiting: French National Database of Rare Dermatological Cancers (NCT03210935)
WHY IT MATTERS
If you have been diagnosed with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma, you may be eligible to join this large French national study that could help shape future treatment approaches for these poorly understood skin cancers.
Researchers in France are looking for 9,000 patients with three rare types of skin cancer: Merkel cell carcinoma, advanced basal cell carcinoma, and adnexal tumors of the skin. This study will collect information about how these cancers develop, how they respond to treatment, and how they affect patients' lives. The goal is to better understand these uncommon cancers so doctors can improve care in the future.
NCT ID: NCT03210935 Status: RECRUITING Conditions: Adnexal Tumor of Skin, Merkel Cell Carcinoma, Advanced Basal Cell Carcinoma Requiring Systemic Treatment Enrollment: 9000 Sponsor: University Hospital, Lille Summary: Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : * to provide epidemiological, clinical and socio-economic characteristics of patients * to identify new clinical or epidem
YOU CAN ACT ON THIS
If you have one of these three rare skin cancers and are in France, contact the University Hospital in Lille (the trial sponsor) to ask about enrollment eligibility and next steps.